CR20210548A - Materiales y métodos para modular la inmunidad mediada por células t - Google Patents

Materiales y métodos para modular la inmunidad mediada por células t

Info

Publication number
CR20210548A
CR20210548A CR20210548A CR20210548A CR20210548A CR 20210548 A CR20210548 A CR 20210548A CR 20210548 A CR20210548 A CR 20210548A CR 20210548 A CR20210548 A CR 20210548A CR 20210548 A CR20210548 A CR 20210548A
Authority
CR
Costa Rica
Prior art keywords
methods
antibodies
modulating
cell
materials
Prior art date
Application number
CR20210548A
Other languages
English (en)
Inventor
Iqbal S Grewal
Sanjaya Singh
Rajkumar Ganesan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CR20210548A publication Critical patent/CR20210548A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos anti-TRGV9 o fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y métodos para usar los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer.
CR20210548A 2019-05-08 2020-05-07 Materiales y métodos para modular la inmunidad mediada por células t CR20210548A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962844976P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
US201962844966P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Publications (1)

Publication Number Publication Date
CR20210548A true CR20210548A (es) 2022-02-11

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210548A CR20210548A (es) 2019-05-08 2020-05-07 Materiales y métodos para modular la inmunidad mediada por células t

Country Status (22)

Country Link
US (2) US11667712B2 (es)
EP (1) EP3965818A4 (es)
JP (2) JP7686571B2 (es)
KR (1) KR20220017892A (es)
CN (1) CN113966231B (es)
AU (1) AU2020267504A1 (es)
BR (1) BR112021022089A2 (es)
CA (1) CA3139508A1 (es)
CL (1) CL2021002905A1 (es)
CO (1) CO2021015998A2 (es)
CR (1) CR20210548A (es)
DO (1) DOP2021000229A (es)
EC (1) ECSP21087921A (es)
IL (1) IL287817A (es)
JO (1) JOP20210297A1 (es)
MA (1) MA55903A (es)
MX (1) MX2021013532A (es)
PE (1) PE20220763A1 (es)
PH (1) PH12021552790A1 (es)
SG (1) SG11202112021QA (es)
TW (1) TW202108618A (es)
WO (1) WO2020227457A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016212777B2 (en) 2015-01-27 2021-11-18 LAVA Therapeutics N.V. Single domain antibodies targeting CD1d
BR112021005184A8 (pt) 2018-09-19 2022-08-16 Lava Therapeutics B V Imunoglobulina cd1d de dupla ação
CA3145517A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Novel anti-tcr delta variable 1 antibodies
KR20220147631A (ko) * 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
TW202233674A (zh) 2020-10-28 2022-09-01 美商健生生物科技公司 用於調節δγ鏈介導之免疫的組成物及方法
US11639396B2 (en) * 2021-02-16 2023-05-02 Janssen Biotech, Inc. Antibody binding to a linker peptide
BR112023017099A2 (pt) 2021-02-26 2023-11-21 Lava Therapeutics N V Anticorpos que se ligam a cd123 e a receptores de células t gama-delta
CN121909213A (zh) * 2023-07-26 2026-04-21 詹森生物科技公司 用于细胞生长的材料和方法
TW202537974A (zh) * 2023-11-15 2025-10-01 大陸商上海盛迪醫藥有限公司 Ｔｒｇｖ９結合蛋白及其醫藥用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2698880B1 (fr) * 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1461082A4 (en) 2001-12-03 2006-06-28 Abgenix Inc ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX)
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BR112012004777A2 (pt) 2009-09-03 2019-09-24 Genentech Inc métodos para tratar diagnósticar e monitorar artrite reumatoide
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
ES2633145T3 (es) 2010-08-05 2017-09-19 Anaptysbio, Inc. Anticuerpos dirigidos contra IL-17
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
EP3321286B1 (en) 2011-08-23 2021-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
JP6441079B2 (ja) * 2011-12-19 2018-12-19 シンイミューン ゲーエムベーハー 二重特異性抗体分子
CN105848484A (zh) * 2013-10-25 2016-08-10 得克萨斯州大学系统董事会 用于免疫治疗的多克隆γδ T细胞
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
DK3189081T3 (da) 2014-09-05 2020-05-04 Janssen Pharmaceutica Nv Cd123-bindende midler og anvendelser deraf
IL252131B2 (en) 2014-11-17 2023-04-01 Adicet Bio Inc Transgenic gamma delta T cells
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US11117963B2 (en) 2016-12-26 2021-09-14 Kyowa Hakko Kirin Co., Ltd. Antibody which binds to myelin oligodendrocyte glycoprotein
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
EP3743081A4 (en) * 2018-01-23 2021-12-01 New York University SPECIFIC ANTIBODIES OF THE DELTA 1 CHAIN OF THE T-LYMPHOCYTE RECEPTOR
KR20220147631A (ko) 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
TW202233674A (zh) 2020-10-28 2022-09-01 美商健生生物科技公司 用於調節δγ鏈介導之免疫的組成物及方法

Also Published As

Publication number Publication date
PH12021552790A1 (en) 2022-09-05
WO2020227457A1 (en) 2020-11-12
PE20220763A1 (es) 2022-05-16
MA55903A (fr) 2022-03-16
CA3139508A1 (en) 2020-11-12
EP3965818A4 (en) 2023-05-31
TW202108618A (zh) 2021-03-01
JP2022533538A (ja) 2022-07-25
IL287817A (en) 2022-01-01
ECSP21087921A (es) 2022-01-31
CN113966231A (zh) 2022-01-21
US20210032338A1 (en) 2021-02-04
CL2021002905A1 (es) 2022-06-17
JP7686571B2 (ja) 2025-06-02
DOP2021000229A (es) 2022-07-31
US11667712B2 (en) 2023-06-06
US20240150464A1 (en) 2024-05-09
KR20220017892A (ko) 2022-02-14
EP3965818A1 (en) 2022-03-16
JP2024170410A (ja) 2024-12-10
SG11202112021QA (en) 2021-11-29
MX2021013532A (es) 2022-02-11
CO2021015998A2 (es) 2021-12-10
AU2020267504A1 (en) 2021-12-02
BR112021022089A2 (pt) 2022-02-08
CN113966231B (zh) 2025-04-01
JOP20210297A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
ECSP21087921A (es) Materiales y métodos para modular la inmunidad mediada por células t
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
UY39416A (es) Moléculas de direccionamiento inmunes multiespecíficas y usos de estas
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MX2022012628A (es) Anticuerpos anti-phf-tau y usos de estos.
UY39415A (es) Métodos y composiciones para modular la inmunidad mediada por cadenas beta
CO2019009815A2 (es) Combinaciones farmacéuticas
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
CO2022001977A2 (es) Anticuerpos anti-cd96 y sus métodos de uso
UY39127A (es) Materiales y métodos para modular la inmunidad mediada por cadena delta
EA202190807A1 (ru) Антитела к синуклеину
UY39699A (es) Anticuerpos anti-tau y usos de estos
MX2021015501A (es) Anticuerpos y metodos de uso.
EA202092122A1 (ru) Антитела против tip-1 и их применения
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
MX2021009767A (es) Moleculas de union de fmcr y usos de las mismas.
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
MX2024005336A (es) Composiciones y metodos para la modulacion de inmunidad mediada por cadena beta.
AR115424A1 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33 / anti-cd3 y usos de estos
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
AR122715A1 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina